ERBB2 and cancer: Identification of novel vulnerabilities is a main goal in cancer and, particularly in luminal B tumors, where the coexistence of two pathways, the ER and HER2 oncoprotein, drives the disease, and in those tumors where anti-HER2 therapeutic strategies have failed after a given period of treatment.